Clinical Trials Logo

Clinical Trial Summary

The proposed research project aims to answer the question "Are immersive technology systems effective in the management and treatment of patients with BPSD?". This project is composed of three phases and the current study is the first phase. The phase 1 trial aims to create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population.


Clinical Trial Description

The participants will undergo an intervention using the assigned ImGTS for four sessions (twice a week for two weeks), with a maximum of 45 minutes per session. VR trials are in 10- to 20-minute periods with introduction, orientation, and provisions for rest periods for patient comfort. During the experience, documentation of the patient's reaction and interaction with the ImGTS will be recorded by the researchers. The participants will be staying at the designated laboratory for not more than one hour. Demographic characteristics Demographic characteristics of the participant (age, sex, educational attainment, marital status, living conditions, hobbies and interests, previous experience with VE applications, existing illnesses, medications) will be collected by the researchers through a questionnaire. Personal data, such as name and contact information, will only be collected to allow the investigators to contact the participants, as needed. Safety Safety will be ensured by assessing a participant's experience of cybersickness. A cybersickness questionnaire, the Virtual Reality Sickness Questionnaire will be administered after each session. In this self-report questionnaire, nine symptoms will be rated as absent/none, slight, moderate, or severe. These symptoms are general discomfort, fatigue, eyestrain, difficulty focusing, headache, fullness of head, blurred vision, dizziness when the eyes are closed, and vertigo. Answering the questionnaire will take around 10 minutes. In the event that a participant will experience severe cybersickness, they may opt to discontinue the experience. They will be instructed to remove the HMD or to step out of the Semi-CAVE room to rest and recover from the symptoms. A medical professional will be present to monitor the participant's symptoms and to attend to them for further management. The reason(s) for discontinuing the experience will be documented. Acceptability The acceptability of the design will be measured using the Place Probe, a sense of place questionnaire. The questionnaire will be administered after each session, and it will collect information on a participant's experience in the VE application, particularly on (a) their general impression of the environment, (b) the key features of the environment, and (c) their feelings of presence. A positive general impression, a memorable environment, and high level of presence will indicate that the VE developed is acceptable. This will take about 10 minutes to complete. Usability Usability testing will be performed according to the PNS ISO/IEC Metrics. The goal is to provide continuous improvement in the design and user experience to maximize the three components of usability: effectiveness, efficiency, and satisfaction. Additional usability metrics will be identified during the first phase of the study. The metrics will be specifically adjusted to the target participants as well as the contents to be included in the VR system. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05265182
Study type Interventional
Source Augmented eXperience E-health Laboratory
Contact
Status Completed
Phase N/A
Start date April 28, 2022
Completion date July 26, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT03378245 - Telemedicine-based, Multidisciplinary-team, Intervention to Reduce Unnecessary Hospitalizations N/A
Recruiting NCT04871698 - On Site Sensors Monitoring Impacts of Cognitive Decline on ADLs
Active, not recruiting NCT05847153 - MASC: Reducing Stress for Caregivers N/A
Recruiting NCT04863859 - Persons With Dementia and Their Extended Family Caregivers
Active, not recruiting NCT05529277 - Implementing Dementia Care Management Into Routine Care in the Region Siegen-Wittgenstein
Active, not recruiting NCT03631069 - Detecting Dementia in the Retina Using Optical Coherence Tomography
Not yet recruiting NCT06047340 - Feasibility Study of Game Technology in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease N/A
Terminated NCT03682874 - Identifying Novel Aging Targets for Treatment of Delirium
Completed NCT03907748 - Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia N/A
Completed NCT04058886 - Telephone-delivered Mindfulness Intervention for African American Dementia Caregivers N/A
Not yet recruiting NCT05606445 - Surface EMG to Measure Paratonia in Dementia
Recruiting NCT04308512 - Care Coordination System for People With Dementia Phase 1/Phase 2
Active, not recruiting NCT03943641 - Dementia Risk Prediction Model: Development and Validation
Not yet recruiting NCT05245903 - Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
Not yet recruiting NCT06396377 - Interest of the Reborn® Doll as a TO in the Care of Residents With Alzheimer's Disease or a Related Disorder N/A
Recruiting NCT03472482 - Optical Coherence Tomography in Cerebral Amyloidosis
Recruiting NCT04313582 - Feasibility of the SmartPrompt for Improving Everyday Function in Dementia N/A
Recruiting NCT05315895 - The Dampness Syndrome of Chinese Medicine Cohort Study
Completed NCT04462029 - A Study to Compare the Pharmacokinetics of BR4002 and BR4002-1 in Healthy Volunteers Early Phase 1